# **Clinical Guideline Statement**

# **Haematology Site Specific Group**

**VERSION CONTROL**

THIS IS A CONTROLLED DOCUMENT - PLEASE ARCHIVE ALL PREVIOUS VERSIONS ON RECEIPT OF THE CURRENT VERSION.

Please check the Peninsula Cancer Alliance website for the latest available version: <https://peninsulacanceralliance.nhs.uk/site-specific-groups/haemato-oncology-ssg/>

The Haematology SSG will evaluate and update these guidelines on an annual basis, via the PCA SSG meetings, taking into account advancements and/or changes to relevant healthcare policies/clinical guidelines and evidence based research.

It is expected that all Trusts within the Peninsula Cancer Alliance will be able to meet the standards of care recommended within these guidelines.

|  |  |  |  |
| --- | --- | --- | --- |
| **VERSION** | **DATE ISSUED** | **SUMMARY OF CHANGE** | **OWNER** |
| 0.1  | JANUARY 2020  | First draft  | PCA Haematology SSG  |
| 0.2 | SEPTEMBER 2020 | Second Draft  | PCA Haematology SSG |
| 1.0 | FEBRUARY 2022 | Final Agreed  | PCA Haematology SSG |

This document has been prepared by:

Beth Kingshott, Peninsula Cancer Alliance SSG Support Manager

These clinical guidelines have been agreed on behalf of the PCA Haematology SSG:

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** |  **Position** | **Organisation** | **Date agreed** |
| Dr Jason Coppell | Consultant Haematologist  | Royal Devon and ExeterNHS Foundation TrustNorthern Devon Healthcare NHS Trust | **03/02/2022** |
| Dr Michelle Furtado (SSG Chair) | Consultant Haematologist | Royal Cornwall Hospitals NHS Trust | **03/02/2022** |
| Dr Hannah Hunter | Consultant Haematologist | Plymouth Hospitals NHS Trust | **03/02/2022** |
| Dr Heather Eve | Consultant Haematologist | Torbay and South Devon NHS Foundation Trust | **03/02/2022** |

# **Clinical Guidelines (NS/Haem/g-17-101)**

The Peninsula Cancer Alliance Haematology SSG refers to the following protocols for the management of Haematological cancers/ disorders;

**Thames Valley Strategic Clinical Network Site Specific Group Protocols**

<http://nssg.oxford-haematology.org.uk/>

*NB: These guidelines are used as a reference only at the clinician’s responsibility. The Peninsula Cancer Alliance Haematology SSG has not contributed to the preparation of these protocols.*

**Generic Guidelines**

The PCA Haematology SSG also refers to the following generic guidelines produced by the National Institute for Health and Care Excellence (NICE) as a framework to inform the delivery of evidence based care to Haematological cancer patients;

* National Institute for Health and Care Excellence. (2016). Haematological Cancers: Improving Outcomes [NG47]. <https://www.nice.org.uk/guidance/ng47>

The PCA Haematology SSG also refers to the following regionally agreed pathway:

[Royal Cornwall NHS Trust. Lymphoma Treatment Pathways, 2019 ( revised 2022) V 9.0](%5C%5C%5C%5Cexe.nhs.uk%5C%5Cpublic%5C%5CCANCER%20NETWORK%5C%5CCANCER%20ALLIANCE%20WORK%202017%20ONWARDS%5C%5CSITE%20SPECIFIC%20GROUPS%5C%5CHaematology%5C%5CClinical%20Guidelines%5C%5Cagreed%20guidelines%20and%20protocols%5C%5CRCHT%20Lymphoma%20Pathways%20V.9.pdf)

**Sub-Speciality Leads**

The PCA Haematology SSG has allocated sub-speciality leads from across the Peninsula who can be contacted for specialist advice/ guidance and support.

[PCA Haem SSG Sub-Speciality Leads, 2022 V2.0.pdf](file:///%5C%5Cexe.nhs.uk%5Cpublic%5CCANCER%20NETWORK%5CCANCER%20ALLIANCE%20WORK%202017%20ONWARDS%5CSITE%20SPECIFIC%20GROUPS%5CHaematology%5CClinical%20Guidelines%5Csub%20speciality%20leads%5CPCA%20Haem%20SSG%20Sub-Speciality%20Leads%20V2.0.pdf)

**Clinical Trials**

The PCA Haematology SSG is committed to offering all eligible patient entry into clinical trials where available. There are clinical trials open in each centre. Please liaise with the Research and Development department.